Rheumatologists need to learn how to manage the significant inflammatory side effects experienced by many patients whose cancer is being treated with checkpoint inhibitors, according to presenters at EULAR 2018 in Amsterdam. Immune-related adverse events (irAEs) are becoming a major issue with checkpoint inhibitors, such as anti-CTA4 (ipilimumab), anti-PD-1 (nivolumab, pembrolizumab) and anti PD-L1 (atezoluzumab, ...
Prepare to manage inflammatory adverse events with checkpoint inhibitors, rheumatologists told
By Ingrid Torjesen
25 Jun 2018